Pluri Business Summary

Pluri Inc. (PLUR) operates a multi-sector biotechnology business model centered on its proprietary 3D cell expansion technology, generating revenue through a mix of clinical development, strategic licensing, and its Contract Development and Manufacturing Organization (CDMO) services. The company’s primary segments include regenerative medicine (cell therapy), FoodTech (cultivated meat and coffee), AgTech, and industrial-scale manufacturing via its PluriCDMO™ division. By leveraging its placenta-derived PLX cell platform, Pluri has expanded beyond human therapeutics into high-growth biofarming ventures, such as its Kokomodo cacao acquisition and Ever After Foods joint venture. In the competitive landscape, Pluri contends with specialized biotech firms like Sarepta Therapeutics, Celularity, and Atara Biotherapeutics; however, it distinguishes itself as a diversified platform play rather than a pure-play therapeutic developer, currently navigating a Nasdaq compliance cure period while seeking to monetize its scalable manufacturing infrastructure. The company is led by CEO and President Yaky Yanay, a long-standing executive who has steered the firm’s transition from Pluristem Therapeutics into a multi-vertical technology provider. The leadership team includes Chief Technology Officer Lior Raviv, who oversees the proprietary expansion platforms, and Chief Scientific Officer Artur Machlenkin, a veteran of Compugen with deep expertise in drug discovery. In December 2025, Pluri underwent a significant governance shift with the appointment of Alejandro Weinstein as Chairman of the Board; Weinstein is a prominent global investor known for leading CFR Pharmaceuticals to a $2.9 billion exit to Abbott. His involvement is backed by a substantial 30% ownership stake through Chutzpah Holdings Ltd., joining other notable institutional investors such as Merchant Adventure Investment Advisors. The board also retains the expertise of Vice Chairman Zami Aberman, who served as Chairman for two decades, ensuring continuity from the company’s founding roots in Haifa’s Matam Park.